Form 4: Sarepta Therapeutics President Reports Stock Transaction
Insider Transaction (Form 4)
Louise Rodino-Klapac, President, R&D and Tech Ops of Sarepta Therapeutics, Inc., reported a transaction in 21,423 shares of common stock on September 4, 2026.
Summary
- Tax/exercise-price withholding: disposed of 21,423 Common Stock at $22.22 ($476,019) on September 4, 2026; holds 203,900 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Louise Rodino-Klapac — Officer (President, R&D and Tech Ops)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-04 | Tax/exercise-price withholding | Common Stock | 21,423 | $22 | $476.0K | 203,900 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-04 | Tax/exercise-price withholding (21,423 shares) |
Keywords
insider transaction, Form 4, SRPT, Sarepta Therapeutics, Inc., neutral, Louise Rodino-Klapac
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.